Stem cell therapies for neurological disease are not one thing—they split into three distinct strategies with very different success rates

MSCs dominate 83% of neurological stem cell trials, but the clearest success story is not MSCs at all. It is hematopoietic stem cell transplantation for aggressive multiple sclerosis. The reason reveals something important about when cell therapy works—and when it fails.